Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 11/20 | 0.70 |
| ▸ | KIT | P10721 | 4/20 | 0.70 |
| ▸ | KDR | P35968 | 8/20 | 0.68 |
| ▸ | AXL | P30530 | 3/20 | 0.67 |
| ▸ | MET | P08581 | 4/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189185 | 0.94 | PDGFRA (0.71) | PDGFRAKITKDRAXLMET | |
| SCHEMBL5815596 | 0.92 | PDGFRA (0.69) | PDGFRAKITKDRAXLMET | |
| SCHEMBL4223563 | 0.92 | PDGFRA (0.81) | PDGFRAKITKDRAXLMET | |
| SCHEMBL5814824 | 0.91 | PDGFRA (0.68) | PDGFRAKITKDRAXLMET | |
| SCHEMBL2063467 | 0.89 | PDGFRA (0.65) | PDGFRAKITKDRAXLMET | |
| SCHEMBL2063474 | 0.89 | PDGFRA (0.65) | PDGFRAKITKDRAXLMET | |
| SCHEMBL2064560 | 0.89 | PDGFRA (0.65) | PDGFRAKITKDRAXLMET | |
| SCHEMBL2062554 | 0.88 | PDGFRA (0.71) | PDGFRAKITKDRAXLMET | |
| SCHEMBL2064084 | 0.88 | PDGFRA (0.71) | PDGFRAKITKDRAXLMET | |
| SCHEMBL2063288 | 0.87 | PDGFRA (0.65) | PDGFRAKITKDRAXLMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006117570-A1 | QUINOLINE DERIVATIVES AS KINASE ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |